Arcturus Therapeutics (ARCT) Tops Q4 EPS by 25c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.47), $0.25 better than the analyst estimate of ($1.72). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• The Children's Place (PLCE) PT Lowered to $3.25 at UBS on Soft Sales Trends
• Chilean Cobalt completes Phase 2 at NeoRe project, gets $1.5M investment